DiaMedica Therapeutics (DMAC) Income from Continuing Operations (2018 - 2026)
DiaMedica Therapeutics (DMAC) posted quarterly Income from Continuing Operations of 10042000.0 for Q1 2026, down 30.3% year-over-year from 14406867.83 in Q1 2025, and down 164.19% quarter-over-quarter from 3801000.0 in Q4 2025.
DiaMedica Therapeutics (DMAC) Income from Continuing Operations (2018 - 2026) Analysis & Trends
DiaMedica Therapeutics' Income from Continuing Operations history runs 9 years deep, the most recent figure standing at 10042000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 30.3% year-over-year to 10042000.0; the TTM figure through Mar 2026 stood at 30162000.0 (down 11.71% YoY), while the FY2025 annual figure was 27827000.0, down 13.84% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 10042000.0, down from 3801000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 3059000.0 in Q3 2022, with the low at 10042000.0 in Q1 2026.
- The 5-year median for Income from Continuing Operations is 5151000.0 (2024), against an average of 5610000.0.
- The sharpest annual moves came in 2024 and 2025: Income from Continuing Operations tumbled 53.07% in 2024, then surged 51.89% in 2025.
- DiaMedica Therapeutics' Income from Continuing Operations stood at 3751000.0 in 2022, then tumbled by 37.59% to 5161000.0 in 2023, then plunged by 53.07% to 7900000.0 in 2024, then jumped by 51.89% to 3801000.0 in 2025, then plunged by 164.19% to 10042000.0 in 2026.
- Business Quant data shows DMAC's Income from Continuing Operations at 10042000.0 in Q1 2026, 3801000.0 in Q4 2025, and 8620000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | DiaMedica Therapeutics | 360.22 Mn | 360.22 Mn | - | -10.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -10.14 Mn |
| Mar 31, 2026 | -10.04 Mn |
| Dec 31, 2025 | -3.80 Mn |
| Sep 30, 2025 | -8.62 Mn |
| Jun 30, 2025 | -7.70 Mn |
| Mar 31, 2025 | -7.71 Mn |
| Dec 31, 2024 | -7.90 Mn |
| Sep 30, 2024 | -6.27 Mn |
| Jun 30, 2024 | -5.12 Mn |
| Mar 31, 2024 | -5.15 Mn |
| Dec 31, 2023 | -5.16 Mn |
| Sep 30, 2023 | -4.47 Mn |
| Jun 30, 2023 | -4.48 Mn |
| Mar 31, 2023 | -5.27 Mn |
| Dec 31, 2022 | -3.75 Mn |
| Sep 30, 2022 | -3.06 Mn |
| Jun 30, 2022 | -3.36 Mn |
| Mar 31, 2022 | -3.51 Mn |
| Dec 31, 2021 | -3.25 Mn |
| Sep 30, 2021 | -3.45 Mn |